Parallel Advisors, LLC Amgen Inc Transaction History

Parallel Advisors, LLC

$3.87 Billion
Q2 2024

A detailed history of Parallel Advisors, LLC transactions in Amgen Inc stock. As of the latest transaction made, Parallel Advisors, LLC holds 9,210 shares of AMGN stock, worth $2.91 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares

9,210

Previous 9,140 0.77%

Holding current value

$2.91 Million

Previous $2.6 Million 10.74%

% of portfolio

0.07%

Previous 0.07%

33 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 08, 2024	BUY	$262.75 - $319.31 $18,392 - $22,351	70 Added 0.77%	9,210 $2.88 Million
Q1 2024 May 06, 2024	BUY	$268.87 - $324.56 $50,009 - $60,368	186 Added 2.08%	9,140 $2.6 Million
Q4 2023 Feb 09, 2024	SELL	$255.7 - $288.46 $114,042 - $128,653	-446 Reduced 4.74%	8,954 $2.58 Million
Q3 2023 May 20, 2024	BUY	$218.65 - $271.46 $230,675 - $286,390	1,055 Added 12.64%	9,400 $2.53 Million
Q3 2023 Nov 13, 2023	BUY	$218.65 - $271.46 $230,675 - $286,390	1,055 Added 12.64%	9,400 $2.53 Million
Q2 2023 May 20, 2024	SELL	$214.27 - $253.37 $372,829 - $440,863	-1,740 Reduced 17.25%	8,345 $1.85 Million
Q2 2023 Aug 04, 2023	SELL	$214.27 - $253.37 $372,829 - $440,863	-1,740 Reduced 17.25%	8,345 $1.85 Million
Q1 2023 May 20, 2024	BUY	$225.79 - $275.2 $213,371 - $260,064	945 Added 10.34%	10,085 $2.44 Million
Q1 2023 Apr 25, 2023	BUY	$225.79 - $275.2 $184,244 - $224,563	816 Added 8.8%	10,085 $2.44 Million
Q4 2022 Feb 03, 2023	SELL	$229.03 - $291.01 $1,145 - $1,455	-5 Reduced 0.05%	9,269 $2.43 Million
Q3 2022 Nov 10, 2022	BUY	$224.46 - $253.15 $91,804 - $103,538	409 Added 4.61%	9,274 $2.09 Million
Q2 2022 Aug 01, 2022	BUY	$230.71 - $256.74 $42,450 - $47,240	184 Added 2.12%	8,865 $2.16 Million
Q1 2022 Apr 28, 2022	BUY	$219.27 - $242.57 $218,392 - $241,599	996 Added 12.96%	8,681 $2.11 Million
Q4 2021 Jan 20, 2022	BUY	$198.88 - $227.6 $131,459 - $150,443	661 Added 9.41%	7,685 $1.73 Million
Q3 2021 Nov 02, 2021	SELL	$212.27 - $248.7 $62,831 - $73,615	-296 Reduced 4.04%	7,024 $1.49 Million
Q2 2021 Aug 06, 2021	SELL	$233.58 - $259.14 $17,518 - $19,435	-75 Reduced 1.01%	7,320 $1.78 Million
Q1 2021 Apr 23, 2021	BUY	$221.91 - $258.6 $107,404 - $125,162	484 Added 7.0%	7,395 $1.84 Million
Q4 2020 Feb 02, 2021	SELL	$216.38 - $257.67 $444,011 - $528,738	-2,052 Reduced 22.89%	6,911 $1.59 Million
Q3 2020 Oct 27, 2020	BUY	$234.65 - $260.95 $170,825 - $189,971	728 Added 8.84%	8,963 $2.28 Million
Q2 2020 Jul 16, 2020	BUY	$197.81 - $242.74 $65,079 - $79,861	329 Added 4.16%	8,235 $1.94 Million
Q1 2020 Apr 27, 2020	SELL	$182.24 - $241.7 $129,025 - $171,123	-708 Reduced 8.22%	7,906 $1.6 Million
Q4 2019 Jan 30, 2020	BUY	$189.21 - $243.2 $92,334 - $118,681	488 Added 6.01%	8,614 $2.08 Million
Q3 2019 Nov 01, 2019	BUY	$174.11 - $208.62 $150,256 - $180,039	863 Added 11.88%	8,126 $1.57 Million
Q2 2019 Aug 05, 2019	SELL	$166.7 - $195.41 $9,168 - $10,747	-55 Reduced 0.75%	7,263 $1.34 Million
Q1 2019 May 01, 2019	SELL	$180.87 - $203.88 $92,605 - $104,386	-512 Reduced 6.54%	7,318 $1.39 Million
Q4 2018 Feb 05, 2019	SELL	$178.4 - $208.25 $5,173 - $6,039	-29 Reduced 0.37%	7,830 $1.52 Million
Q3 2018 Nov 01, 2018	BUY	$185.29 - $208.89 $296,278 - $334,015	1,599 Added 25.54%	7,859 $1.63 Million
Q2 2018 Jul 30, 2018	BUY	$166.05 - $186.51 $174,186 - $195,648	1,049 Added 20.13%	6,260 $1.16 Million
Q1 2018 May 08, 2018	SELL	$169.43 - $198.0 $32,699 - $38,214	-193 Reduced 3.57%	5,211 $888,000
Q4 2017 Feb 13, 2018	SELL	$168.79 - $188.59 $7,089 - $7,920	-42 Reduced 0.77%	5,404 $940,000
Q3 2017 Nov 15, 2017	BUY	$167.29 - $191.0 $911,061 - $1.04 Million	5,446 New	5,446 $934,000
Q3 2017 Nov 14, 2017	SELL	$167.29 - $191.0 $882,454 - $1.01 Million	-5,275 Closed	0 $0
Q2 2017 Aug 07, 2017	BUY	N/A	5,275	5,275 $920,000

Others Institutions Holding AMGN

# of Institutions

3,073

Shares Held

417M

Call Options Held

7.19M

Put Options Held

6.28M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $169B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.

Account

Parallel Advisors, LLC Amgen Inc Transaction History